Remove 2026 Remove Healthcare Remove Pharma
article thumbnail

Pharma contract manufacturing market to grow to $130bn by 2026

European Pharmaceutical Review

billion by 2026. In addition, investigators cited the increasing geriatric patient population, growing consumption of medicines, rising healthcare expenditure, improving healthcare infrastructure in emerging markets and mounting pressure to reduce healthcare costs as other factors driving market growth. Within the $130.2

article thumbnail

In long-acting HIV PrEP access showdown with Gilead, GSK moves to triple Apretude supply for certain countries

Fierce Pharma

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CPHI Pharma Awards 2023 finalists announced

European Pharmaceutical Review

For its 20 th anniversary, more than 180 entries across 12 categories have been narrowed down to determine the finalists the upcoming CPHI Pharma Awards. To recognise the influx of innovation across the pharmaceutical industry, three new categories are included in this year’s awards.

Pharma 119
article thumbnail

NewAmsterdam Pharma enters merger deal with Frazier Lifesciences

Pharmaceutical Technology

NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). The SPAC is sponsored by a Frazier Healthcare Partners affiliate.

Pharma 59
article thumbnail

Connected customer data: a golden opportunity for pharma marketers

pharmaphorum

Approximately 30% of global data volume is generated by the healthcare industry and it will continue to expand with a compound annual growth rate predicted to reach 36% by 2025, according to research by RBC Capital Markets. Pharma is a highly regulated industry and that is often why it is slow to adopt new technologies,” says Kazuki.

article thumbnail

Health consumers: A long way off

World of DTC Marketing

We keep hearing the term “consumers of health” but the American healthcare system is too profitable to allow people to be consumers of healthcare. What if … people got a fair ROI for healthcare spending the way we expect a reasonable return from other investments? By 2026, national health expenditures will reach $5.7

article thumbnail

Pharma-biotech dealmaking incentives shift amid a continued drought in financing

Clarivate

These years witnessed significant troughs in pharma financing, a drop in the capital markets, and an IPO window that remained firmly shut. Big pharma is still keen to access good technology, science, and assets, in many cases to plug a patent-expiry-shaped hole in their coffers. In short, the biotech bubble had burst. Pfizer’s $11.6

Pharma 52